Loading…

Comparison of efficacy and safety of traditional Chinese patent medicines for diabetic nephropathy

Background:. Diabetic nephropathy (DN) is one of the most serious complications of diabetes. It has become a global public health problem among humans. DN is the leading cause of end-stage renal disease. At present, there is no specific medicine or modern medicinal therapy. In recent years, studies...

Full description

Saved in:
Bibliographic Details
Published in:Medicine (Baltimore) 2022-05, Vol.101 (19), p.e29152
Main Authors: Shilin Liu, MD, PhD, Andong Li, MD, PhD, Bin Jiang, BS, Jia Mi, MD, PhD, Hongmei Nan, MD, PhD, Pengjie Bao, MD, PhD, Zheng Nan, BS
Format: Article
Language:English
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c1612-c3c27ee1ff07b4631ee05a522cf3dc7ceffeec46ccc6c75d623ef9db6e100ee3
cites
container_end_page
container_issue 19
container_start_page e29152
container_title Medicine (Baltimore)
container_volume 101
creator Shilin Liu, MD, PhD
Andong Li, MD, PhD
Bin Jiang, BS
Jia Mi, MD, PhD
Hongmei Nan, MD, PhD
Pengjie Bao, MD, PhD
Zheng Nan, BS
description Background:. Diabetic nephropathy (DN) is one of the most serious complications of diabetes. It has become a global public health problem among humans. DN is the leading cause of end-stage renal disease. At present, there is no specific medicine or modern medicinal therapy. In recent years, studies have shown that traditional Chinese patent medicines have been effective in treating DN, with few side effects. There is no systematic review on the treatment of DN with Chinese patent medicines. The current systematic review aims to evaluate the efficacy and safety of Chinese patent medicines for the treatment of DN. Methods:. We will develop a search strategy to search major Chinese and English databases from inception to February 25, 2022 for randomized controlled trials examining the use of traditional Chinese patent medicine for the treatment of DN. The search will be conducted in accordance with the participants, interventions, comparisons, outcomes (PICOS) framework. Two researchers will use EndnoteX9 software to extract data and independently evaluate the quality of the included trials. Finally, the Bayesian network meta-analysis will be carried out by using software such as ReviewManager, Stata16.0, and WinBUGS1.4.3. Results:. The primary outcomes will be urine albumin excretion rate, urea nitrogen, serum creatinine, total effective rate, and adverse events, and the secondary outcomes will be body mass index, fasting blood glucose, and 2-hPG during 75-g OGTT. These outcomes will be examined to provide a reliable basis for the treatment of DN with different traditional Chinese patent medicines. Conclusion:. This review will compare the efficacy and safety of different traditional Chinese patent medicines for treating DN. The results of the study will provide a basis for the selection of adjuvant treatment options for DN.
doi_str_mv 10.1097/MD.0000000000029152
format article
fullrecord <record><control><sourceid>doaj</sourceid><recordid>TN_cdi_doaj_primary_oai_doaj_org_article_28e5a1735d5549f9b9ddeba6ed5a9d9e</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_28e5a1735d5549f9b9ddeba6ed5a9d9e</doaj_id><sourcerecordid>oai_doaj_org_article_28e5a1735d5549f9b9ddeba6ed5a9d9e</sourcerecordid><originalsourceid>FETCH-LOGICAL-c1612-c3c27ee1ff07b4631ee05a522cf3dc7ceffeec46ccc6c75d623ef9db6e100ee3</originalsourceid><addsrcrecordid>eNpFjstOwzAURC0EEqXwBWz8Ayl-xDZeovCqVMSm--jm-pq6auPIySZ_TwtIzGako9HoMHYvxUoK7x4-nlfiP8pLoy7YQhptK-NtfckWJ2oq5119zW7GcS-E1E7VC9Y1-ThASWPueY6cYkwIOHPoAx8h0jSf8VQgpCnlHg682aWeRuIDTNRP_Egh4ZnwmAsPCTqaEvKehl3Jp81uvmVXEQ4j3f31km1fX7bNe7X5fFs3T5sKpZWqQo3KEckYhetqqyWRMGCUwqgDOjypEWFtEdGiM8EqTdGHzpIUgkgv2fr3NmTYt0NJRyhzmyG1PyCXrxbKSe1ArXokA9JpE4ypffSdD4E6sBQM-OBJfwMaMWev</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Comparison of efficacy and safety of traditional Chinese patent medicines for diabetic nephropathy</title><source>HEAL-Link subscriptions: Lippincott Williams &amp; Wilkins</source><source>IngentaConnect Journals</source><source>PubMed Central</source><creator>Shilin Liu, MD, PhD ; Andong Li, MD, PhD ; Bin Jiang, BS ; Jia Mi, MD, PhD ; Hongmei Nan, MD, PhD ; Pengjie Bao, MD, PhD ; Zheng Nan, BS</creator><creatorcontrib>Shilin Liu, MD, PhD ; Andong Li, MD, PhD ; Bin Jiang, BS ; Jia Mi, MD, PhD ; Hongmei Nan, MD, PhD ; Pengjie Bao, MD, PhD ; Zheng Nan, BS</creatorcontrib><description>Background:. Diabetic nephropathy (DN) is one of the most serious complications of diabetes. It has become a global public health problem among humans. DN is the leading cause of end-stage renal disease. At present, there is no specific medicine or modern medicinal therapy. In recent years, studies have shown that traditional Chinese patent medicines have been effective in treating DN, with few side effects. There is no systematic review on the treatment of DN with Chinese patent medicines. The current systematic review aims to evaluate the efficacy and safety of Chinese patent medicines for the treatment of DN. Methods:. We will develop a search strategy to search major Chinese and English databases from inception to February 25, 2022 for randomized controlled trials examining the use of traditional Chinese patent medicine for the treatment of DN. The search will be conducted in accordance with the participants, interventions, comparisons, outcomes (PICOS) framework. Two researchers will use EndnoteX9 software to extract data and independently evaluate the quality of the included trials. Finally, the Bayesian network meta-analysis will be carried out by using software such as ReviewManager, Stata16.0, and WinBUGS1.4.3. Results:. The primary outcomes will be urine albumin excretion rate, urea nitrogen, serum creatinine, total effective rate, and adverse events, and the secondary outcomes will be body mass index, fasting blood glucose, and 2-hPG during 75-g OGTT. These outcomes will be examined to provide a reliable basis for the treatment of DN with different traditional Chinese patent medicines. Conclusion:. This review will compare the efficacy and safety of different traditional Chinese patent medicines for treating DN. The results of the study will provide a basis for the selection of adjuvant treatment options for DN.</description><identifier>ISSN: 0025-7974</identifier><identifier>EISSN: 1536-5964</identifier><identifier>DOI: 10.1097/MD.0000000000029152</identifier><language>eng</language><publisher>Wolters Kluwer</publisher><ispartof>Medicine (Baltimore), 2022-05, Vol.101 (19), p.e29152</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c1612-c3c27ee1ff07b4631ee05a522cf3dc7ceffeec46ccc6c75d623ef9db6e100ee3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Shilin Liu, MD, PhD</creatorcontrib><creatorcontrib>Andong Li, MD, PhD</creatorcontrib><creatorcontrib>Bin Jiang, BS</creatorcontrib><creatorcontrib>Jia Mi, MD, PhD</creatorcontrib><creatorcontrib>Hongmei Nan, MD, PhD</creatorcontrib><creatorcontrib>Pengjie Bao, MD, PhD</creatorcontrib><creatorcontrib>Zheng Nan, BS</creatorcontrib><title>Comparison of efficacy and safety of traditional Chinese patent medicines for diabetic nephropathy</title><title>Medicine (Baltimore)</title><description>Background:. Diabetic nephropathy (DN) is one of the most serious complications of diabetes. It has become a global public health problem among humans. DN is the leading cause of end-stage renal disease. At present, there is no specific medicine or modern medicinal therapy. In recent years, studies have shown that traditional Chinese patent medicines have been effective in treating DN, with few side effects. There is no systematic review on the treatment of DN with Chinese patent medicines. The current systematic review aims to evaluate the efficacy and safety of Chinese patent medicines for the treatment of DN. Methods:. We will develop a search strategy to search major Chinese and English databases from inception to February 25, 2022 for randomized controlled trials examining the use of traditional Chinese patent medicine for the treatment of DN. The search will be conducted in accordance with the participants, interventions, comparisons, outcomes (PICOS) framework. Two researchers will use EndnoteX9 software to extract data and independently evaluate the quality of the included trials. Finally, the Bayesian network meta-analysis will be carried out by using software such as ReviewManager, Stata16.0, and WinBUGS1.4.3. Results:. The primary outcomes will be urine albumin excretion rate, urea nitrogen, serum creatinine, total effective rate, and adverse events, and the secondary outcomes will be body mass index, fasting blood glucose, and 2-hPG during 75-g OGTT. These outcomes will be examined to provide a reliable basis for the treatment of DN with different traditional Chinese patent medicines. Conclusion:. This review will compare the efficacy and safety of different traditional Chinese patent medicines for treating DN. The results of the study will provide a basis for the selection of adjuvant treatment options for DN.</description><issn>0025-7974</issn><issn>1536-5964</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpFjstOwzAURC0EEqXwBWz8Ayl-xDZeovCqVMSm--jm-pq6auPIySZ_TwtIzGako9HoMHYvxUoK7x4-nlfiP8pLoy7YQhptK-NtfckWJ2oq5119zW7GcS-E1E7VC9Y1-ThASWPueY6cYkwIOHPoAx8h0jSf8VQgpCnlHg682aWeRuIDTNRP_Egh4ZnwmAsPCTqaEvKehl3Jp81uvmVXEQ4j3f31km1fX7bNe7X5fFs3T5sKpZWqQo3KEckYhetqqyWRMGCUwqgDOjypEWFtEdGiM8EqTdGHzpIUgkgv2fr3NmTYt0NJRyhzmyG1PyCXrxbKSe1ArXokA9JpE4ypffSdD4E6sBQM-OBJfwMaMWev</recordid><startdate>20220501</startdate><enddate>20220501</enddate><creator>Shilin Liu, MD, PhD</creator><creator>Andong Li, MD, PhD</creator><creator>Bin Jiang, BS</creator><creator>Jia Mi, MD, PhD</creator><creator>Hongmei Nan, MD, PhD</creator><creator>Pengjie Bao, MD, PhD</creator><creator>Zheng Nan, BS</creator><general>Wolters Kluwer</general><scope>DOA</scope></search><sort><creationdate>20220501</creationdate><title>Comparison of efficacy and safety of traditional Chinese patent medicines for diabetic nephropathy</title><author>Shilin Liu, MD, PhD ; Andong Li, MD, PhD ; Bin Jiang, BS ; Jia Mi, MD, PhD ; Hongmei Nan, MD, PhD ; Pengjie Bao, MD, PhD ; Zheng Nan, BS</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c1612-c3c27ee1ff07b4631ee05a522cf3dc7ceffeec46ccc6c75d623ef9db6e100ee3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shilin Liu, MD, PhD</creatorcontrib><creatorcontrib>Andong Li, MD, PhD</creatorcontrib><creatorcontrib>Bin Jiang, BS</creatorcontrib><creatorcontrib>Jia Mi, MD, PhD</creatorcontrib><creatorcontrib>Hongmei Nan, MD, PhD</creatorcontrib><creatorcontrib>Pengjie Bao, MD, PhD</creatorcontrib><creatorcontrib>Zheng Nan, BS</creatorcontrib><collection>Directory of Open Access Journals</collection><jtitle>Medicine (Baltimore)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shilin Liu, MD, PhD</au><au>Andong Li, MD, PhD</au><au>Bin Jiang, BS</au><au>Jia Mi, MD, PhD</au><au>Hongmei Nan, MD, PhD</au><au>Pengjie Bao, MD, PhD</au><au>Zheng Nan, BS</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of efficacy and safety of traditional Chinese patent medicines for diabetic nephropathy</atitle><jtitle>Medicine (Baltimore)</jtitle><date>2022-05-01</date><risdate>2022</risdate><volume>101</volume><issue>19</issue><spage>e29152</spage><pages>e29152-</pages><issn>0025-7974</issn><eissn>1536-5964</eissn><abstract>Background:. Diabetic nephropathy (DN) is one of the most serious complications of diabetes. It has become a global public health problem among humans. DN is the leading cause of end-stage renal disease. At present, there is no specific medicine or modern medicinal therapy. In recent years, studies have shown that traditional Chinese patent medicines have been effective in treating DN, with few side effects. There is no systematic review on the treatment of DN with Chinese patent medicines. The current systematic review aims to evaluate the efficacy and safety of Chinese patent medicines for the treatment of DN. Methods:. We will develop a search strategy to search major Chinese and English databases from inception to February 25, 2022 for randomized controlled trials examining the use of traditional Chinese patent medicine for the treatment of DN. The search will be conducted in accordance with the participants, interventions, comparisons, outcomes (PICOS) framework. Two researchers will use EndnoteX9 software to extract data and independently evaluate the quality of the included trials. Finally, the Bayesian network meta-analysis will be carried out by using software such as ReviewManager, Stata16.0, and WinBUGS1.4.3. Results:. The primary outcomes will be urine albumin excretion rate, urea nitrogen, serum creatinine, total effective rate, and adverse events, and the secondary outcomes will be body mass index, fasting blood glucose, and 2-hPG during 75-g OGTT. These outcomes will be examined to provide a reliable basis for the treatment of DN with different traditional Chinese patent medicines. Conclusion:. This review will compare the efficacy and safety of different traditional Chinese patent medicines for treating DN. The results of the study will provide a basis for the selection of adjuvant treatment options for DN.</abstract><pub>Wolters Kluwer</pub><doi>10.1097/MD.0000000000029152</doi><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0025-7974
ispartof Medicine (Baltimore), 2022-05, Vol.101 (19), p.e29152
issn 0025-7974
1536-5964
language eng
recordid cdi_doaj_primary_oai_doaj_org_article_28e5a1735d5549f9b9ddeba6ed5a9d9e
source HEAL-Link subscriptions: Lippincott Williams & Wilkins; IngentaConnect Journals; PubMed Central
title Comparison of efficacy and safety of traditional Chinese patent medicines for diabetic nephropathy
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T19%3A34%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-doaj&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20efficacy%20and%20safety%20of%20traditional%20Chinese%20patent%20medicines%20for%20diabetic%20nephropathy&rft.jtitle=Medicine%20(Baltimore)&rft.au=Shilin%20Liu,%20MD,%20PhD&rft.date=2022-05-01&rft.volume=101&rft.issue=19&rft.spage=e29152&rft.pages=e29152-&rft.issn=0025-7974&rft.eissn=1536-5964&rft_id=info:doi/10.1097/MD.0000000000029152&rft_dat=%3Cdoaj%3Eoai_doaj_org_article_28e5a1735d5549f9b9ddeba6ed5a9d9e%3C/doaj%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c1612-c3c27ee1ff07b4631ee05a522cf3dc7ceffeec46ccc6c75d623ef9db6e100ee3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true